However, an LT-S1 test concept could provide reliable additional information for the evaluation of COVID-19 patients with regard to eligibility and the usefulness of a monoclonal antibody (mAbs) therapy of acute SARS-CoV-2 infection [19]. This evidence concerns the gene PSMD1 and COVID-19.